| Literature DB >> 29414874 |
Ashar M Farooqi1, Jennifer M Padilla2, Teshamae S Monteith3.
Abstract
The goal of this review is to explore the literature reports of acute confusional migraine (ACM) including patient characteristics, migraine symptomatology, and proposed diagnostic criteria. A literature review was conducted using PubMed, Scopus and Web of Science using the terms "confusional migraine" and "confusional state in migraine". All the relevant articles from 1970 to 2016 were included. A total of 120 patients were found in the literature. Most of the cases were seen in the pediatric population with a slight male predominance. Personal or family history of migraine was common. Most patients had a headache prior to the confusional state. In addition to confusion and agitation, some developed visual (32.5%) and/or sensory symptoms (19%) and/or speech problems (39%) either prior to or during the confusional state. Data on treatment outcomes is lacking. Patients with most common forms of migraine report attention and cognitive disturbances but awareness remains intact as opposed to patients with ACM. ACM is a distinct entity and should be included as part of the appendix of International Classification of Headache Disoders-3 beta version (ICHD-3β) criteria. Prospective studies are needed to further study this disorder and its association with other migraine forms.Entities:
Keywords: International Classification of Headache Disoders-3 beta version; acute confusional migraine; agitation; aura; cognitive; diagnosis; disorientation; migraine variant
Year: 2018 PMID: 29414874 PMCID: PMC5836048 DOI: 10.3390/brainsci8020029
Source DB: PubMed Journal: Brain Sci ISSN: 2076-3425
Figure 1Electronic Literature Search for ACM Cases.
Brief description of previously reported cases of acute confusional migraine including demographic information of the patients (age, gender), clinical presentation (predominant symptoms and percentage of people exhibiting that symptom, onset of headache relative to confusion, duration of confusional state), treatment, and routine follow up if any (recurrence and outcomes) *.
| Case Report (Reference Number) | No. of Patients ( | Gender Ratio (M:F) | Age Range (Years) | Mean Age (Mean ± SD) | Clinical Presentation α | Headache Onset Pre/Post-Confusion | Duration of Confusion (h) | Treatment | Recurrence | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|
| Gascon G. and Barlow C. [ | 4 | 3:1 | 8–16 | 12.3 ± 3.5 | Disorientation (100%), Agitation (100%), Speech (100%), somatosensory (25%) and memory disturbances (50%) | Pre-confusion (4) | 4–24 h | Ergotamine and Phenobarbital | None | Two patients had multiple episodes of headache afterwards |
| Emery III et al. [ | 4 | 3:1 | 5–14 | 10 ± 4.2 | Confusion (100%), agitation (100%), visual (50%), somatosensory (50%) speech (25%), and memory disturbances (75%) | Pre-confusion (4) | 1.5–9 h | NA | Two patients reported similar episodes in the past | Three patients had intermittent episodes of headache |
| Ehayi A. and Fenichel G. M. [ | 5 | 3:2 | 9–14 | 11 ± 2 | Confusion and disorientation (100%), Agitation (100%), visual (80%), somatosensory (20%), speech (40%), motor (20%) and memory disturbances (80%) | Pre- (4), post-confusion (1) | 0.5–24 h | Ergotamine, methysergide | Over brief period of time all patients had recurrent ACM episodes | Migraine |
| Parrino L. et al. [ | 2 | 2:0 | 14–15 | 14.5 ± 0.7 | Confusion and disorientation (100%), agitation (100%), Photophobia (50%), visual (100%), somatosensory (50%), speech (100%), and memory disturbances (100%) | Pre-confusion (2) | 24 h | NA | One patient reported similar episode in the past | None |
| Sacquegna T. et al. 1 [ | 1 | 0:1 | 17 | 17 ± 0 | Confusion and disorientation (100%), visual (100%), somatosensory (100%), and memory disturbances (100%) | Pre-confusion (1) | 2 h | NA | Several episodes marked by less confusion | NA |
| Pietrini V. et al. [ | 12 | 6:6 | 8–60 | 19.4 ± 13.4 | Confusion (100%), agitation (100%), visual (42%), somatosensory (42%), speech (25%), and motor symptoms (17%) | Pre-confusion (10) | 1–12 h | NA | NA | NA |
| Haan J. et al. [ | 1 | 0:1 | 13 | 13 ± 0 | Confusion and disorientation (100%), agitation (100%), memory disturbance (100%) | Pre-confusion (1) | 12 h | NA | One similar episode in the past | NA |
| Piatella L. et al. [ | 5 | 4:1 | 10–16 | 12.6 ± 2.3 | Confusion and disorientation (%100), agitation (20%), speech (80%), somatosensory disturbances (20%) | Pre-confusion (4) 2 | 15 min–24 h | NA | NA | Three patients developed migraine |
| D’Cruz O. and Walsh D. J. [ | 3 | 0:3 | 11 | 11 ± 0 | Confusion and disorientation (100%), speech (67%), visual (67%), memory disturbances (100%) | Pre-confusion (3) | 6 h | NA | NA | NA |
| Sheth R. D. et al. [ | 6 | 1:5 | 7.5–17 | 11.8 ± 3.5 | Confusion and disorientation (100%), agitation (100%), photophobia (50%), visual (50%), memory disturbances (100%) | NA 2 | 1–12 h | Propranolol | Two patients had recurrent ACM episodes | NA |
| Ferrera P. and Reicho P [ | 2 | 1:1 | 6–9 | 7.5 ± 2.1 | Confusion (100%), agitation (50%), visual (50%), somatosensory (100%), speech (50%), and motor disturbances (50%) | Pre-confusion (1) 2 | NA | Sodium Valproate | Both patients had episodes of confusion in past | One patient had 2 episodes of headache |
| Shaabat A. et al. [ | 13 | 11:2 | 6–15 | 10.8 ± 2.9 | Confusion (100%), agitation (62%) | Pre-confusion (13) | 1.5–24 h | NA | Four patients had recurrent ACM episodes | NA |
| Nezu A. et al. [ | 2 | 1:1 | 7–12 | 9.5 ± 3.5 | Confusion (100%), Photophobia (50%), visual (50%), somatosensory (50%), speech (50%), motor (50%) and memory disturbances (100%) | Post-confusion (2) | 6–12 h | Dihydergot | NA | NA |
| Neinstein L. and Milgrom E. [ | 1 | 1:0 | 14 | 14 ± 0 | Confusion (100%), anisocoria (100%), and ataxic gait (100%) | Pre-confusion (1) | NA | High-dose Oxygen and Sumatriptan | One similar episode | NA |
| Soriani S. et al. [ | 11 | 8:3 | 6–14 | 9 ± 3 | Confusion (100%), agitation (45%), somnolence (55%), visual (27%), speech disturbances (9%) | Six patients had headache 3 | 1–12 h | NA | NA | Four patients developed migraine with aura & one w/o aura |
| Al-Twaijri W. and Shevell M. [ | 5 | 2:3 | 6.5–15 | 10.9 | Confused, agitated and memory disturbances 4 | NA 2 | NA | NA | NA | NA |
| Bechtel K. et al. [ | 2 | 1:1 | 11–14 | 12.5 ± 2.1 | Confusion (100%), speech (100%), visual (50%), somatosensory (50%) and memory disturbances (50%) | Pre- (1), post confusion (1) | Several hours | Acetaminophen | None | One patient had several episodes of headache |
| Gascon G. G. et al. [ | 13 | 6:7 | 6–16 | 12.3 ± 3.8 | Confusion (69%), speech (46%), somatosensory (7.7%) and memory disturbances (8%) | Pre- (7), post confusion (4) 3 | NA | NA | Two patients had recurrent episodes of ACM | None |
| Fujita M. et al. [ | 1 | 0:1 | 10 | 10 ± 0 | Confusion and disorientation (100%) visual disturbances (100%) | Pre-confusion (1) | 5–10 h | Sodium Valproate | Recurrent ACM episodes | Attacks were controlled after increasing the dose of sodium valproate |
| Sathe S. et al. [ | 7 | 5:2 | 42–58 | 51.9 ± 7.3 | Confusion (100%), agitation (100%), visual (100%), somatosensory (57%), speech (57%), motor (14%) and memory disturbances (100%) | NA 2 | NA | NA | Recurrent ACM episodes | CADASIL |
| Khatri et al. [ | 2 | 1:1 | 11–16 | 13.5 ± 3.5 | Confusion (100%), speech (50%) and memory disturbances (50%) | Pre-confusion (2) | 0.5–72 h | Prochlorperazine | Recurrent ACM episodes | Prochlorperazine was effective in acute management |
| Avraham S. B. et al. [ | 1 | 1:0 | 12 | 12 ± 0 | Confusion (100%), speech (100%), visual (100%) and somatosensory symptoms (100%) | Pre- (3), during (5), post-confusion (1) | NA | Sodium Valproate | None | None |
| Gantebein A. et al. [ | 10 | 6:4 | 16–62 | 30.5 ± 14.7 | Confusion (100%), agitation (20%), photophobia (10%), visual (40%), somatosensory (10%), motor (10%) speech (40%), and memory disturbances (60%) | Pre- (4), post-confusion (3) 2 | 1–6 h | NA | Seven patients had recurrent confusional episodes | NA |
| Rota E. et al [ | 1 | 0:1 | 12 | 12 ± 0 | Confusion (100%), agitation (100%) | Not specified 2 | 4 h | Topiramate prophylaxis | Previous attack characterized by less agitation | No further episodes of confusion and headache after topiramate |
| Pacheva I. and Ivanov I. [ | 3 | 1:2 | 12–14 | 12.7 ± 1.2 | Confusion (100%), agitation (67%), visual (33%), somatosensory (33%), motor (33%), speech (100%) and memory disturbances (67%) | Pre-confusion (3) | 8–10 h | Diazepam and phenobarbital | None | Two patients had 1–2 episodes of migraine without aura per month |
| Verma R. et al. [ | 1 | 0:1 | 29 | 29 ± 0 | Confusion (100%), Agitation (100%), and memory disturbances (100%) | Pre-confusion (1) | NA | Sodium Valproate | None | NA |
| Kim D. et al. [ | 1 | 0:1 | 9 | 9 ± 0 | Confusion (100%), agitation (100%), speech (100%) and memory disturbance (100%) | NA 2 | 2 h | Propranolol & Flunarizine | Similar episode in the past | Migraine |
| Sato K. et al [ | 1 | 1:0 | 24 | 24 ± 0 | Confusion (100%), agitation (100%), visual (100%) and speech disturbance (100%) | Pre-confusion (1) | NA | Propofol | None | NA |
| Total ( | 68:52 | 5–62 years | Confusion and disorientation (100%), agitation (53%), photophobia (5%), visual (33%), somatosensory (19%), motor (6.7%), speech (39%), memory disturbances (39%) | Pre- (69), post-confusion (11) | 15 min–72 h | ---------- | ---------- | ----------- |
1 The patient had not been labeled as having ACM although the clinical and Electroencephalography (EEG) findings were similar to those seen in ACM; 2 All/some, patients developed headache but its onset relative to confusion and disorientation was not specified; 3 Not all patients in respective case reports and series complained of headache during ACM episode; 4 Information about percentage of people exhibiting that symptom is not specified; * Adapted and modified from previous articles; NA: not available in the particular article; α Sensory symptoms are described as visual and somatosensory symptoms.
Figure 2Schematic distribution of acute confusional migraine among different age groups. The figure shows two-thirds (75%) of the cases occur in people aged <18 years.
Figure 3Percentage of different symptoms reported by the patients with ACM. In addition to confusion, common symptoms include visual, sensory, motor, memory and speech disturbances.
Proposed Classification Criteria for A1.6 Episodic Syndromes that may be associated with migraine: Acute Confusional Migraine.
| (A) At least one attack, fulfilling criteria B to G, not attributed to other medical disorder and/or drug intoxication: |
| (B) At least one of the following: |
Decreased attention Altered awareness Impaired cognition (disorientation and/or deficits in attention, executive function, memory) |
| (C) At least one of the following: |
Agitation or combative behavior Perception disturbances (i.e., visuospatial abnormalities, photophobia) Slowing or frontal intermittent rhythmic delta activity on EEG with complete resolution within a week Aura (reversible visual, sensory, language or brainstem disturbance) for <1 h (typical) |
| (D) Complete resolution within 24 h or after sleep with partial or complete amnesia of event |
| (E) Normal neurological or no persistent neurologic deficit examination following the attack |
| (F) At least one of the following: |
Past medical history of migraine Family history of migraine Headache, if present, may occur before, during and after the confusional state |
| (G) Not attributed to another disorder |